Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?
Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa
Kidney Diseases Associated with Human Immunodeficiency Virus Infection
A Randomized, Controlled Trial of a Behavioral Weight Loss Program for HIV-Infected Patients
CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study
Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection
Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection
Antiretroviral therapy for the prevention of HIV-1 transmission
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy
Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals
Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy
CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection
Ongoing HIV Replication Replenishes Viral Reservoirs During Therapy
Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men
Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy
Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
Published by Pedro CAHN
Updated: 1 January, 2015
There is currently massive research effort to develop a cure for HIV infection, allowing patients to discontinue lifelong combination antiretroviral therapy. New latency-reversing agents may be able to purge the persistent reservoir of latent virus in resting memory CD4+ T cells, but the degree of reservoir reduction needed for cure remains unknown. In this paper, a stochastic model of infection dynamics is presented to estimate the efficacy of latency-reversing agents needed to prevent viral rebound after ART interruption. Clinical data are used to estimate population-level parameter distributions and outcomes. The findings suggest that 2,000-fold reductions are required to permit a majority of patients to interrupt ART for 1 year without rebound and that rebound may occur suddenly after multiple years. Greater than 10,000-fold reductions may be required to prevent rebound altogether. These results predict large variation in rebound times following latency-reversing agents therapy, which will complicate clinical management. This model provides benchmarks for moving latency-reversing agents from the laboratory to the clinic and can aid in the design and interpretation of clinical trials. These results also apply to other interventions to reduce the latent reservoir and can explain the observed return of viremia after months of apparent cure in recent bone marrow transplant recipients and an immediately-treated neonate. .